Patients in the TPC group received a wide range
of chemotherapy agents
96% of patients in the TPC group received chemotherapy
– No patient received best supportive care or biological therapies
*Taxanes: paclitaxel, docetaxel, abraxane , ixabepilone
†
Anthracyclines: doxorubicin, liposomal doxorubicin, mitoxantrone
TPC = treatment of physician’s choice
Cortes J, O’Shaughnessy J et al.
Lancet
. 2011;377:914–923
Total patients N=247
